Children's Place Inc (PLCE): I’m back.

Play Episode

7min

Proactive - Interviews for investors

Chesnara CEO discusses strong 2024 results, dividend growth and M&A outlook

Chesnara PLC (LSE:CSN) CEO Steve Murray talked to Proactive's Stephen Gunnion about the company’s strong 2024 full-year results, highlighting robust cash generation and consistent dividend growth. Murray highlighted that Chesnara generated £60 million in cash over the year, providing strong dividend coverage and supporting its 20-year track record of uninterrupted dividend growth. The business also increased its overall value and maintained a strong solvency position. The interview also covered Chesnara’s acquisition strategy, with Murray detailing the second Canada Life deal, which delivered an uplift in economic value to £11 million—higher than the £8 million initially expected—off a £2 million consideration. He explained that Chesnara currently holds around £200 million in acquisition firepower, supported by a solvency capital ratio of 203%. Murray described the current M&A pipeline as “positive,” noting that a reduction in private equity competition is opening up new opportunities in the UK and Benelux. He also commented on broader macroeconomic conditions, noting that despite some volatility, Chesnara’s long-term outlook remains stable due to natural hedges and long-duration contracts. Looking ahead to 2025, Murray reiterated Chesnara’s confidence in maintaining dividend growth, underpinned by strong visibility on future cash flows well above required commitments. For more CEO interviews and investor insights, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to our channel, and hit the notification bell so you never miss an update. #Chesnara #InsuranceStocks #DividendGrowth #MergersAndAcquisitions #CashGeneration #UKStocks #BeneluxMarkets #CanadaLifeDeal #FinancialResults #InvestorUpdates #ProactiveInvestors

Proactive - Interviews for investors

Airtasker CEO on growth, AI & global expansion

Airtasker Ltd CEO Tim Fung talked with Proactive at AIM's Small and Midcap Conference about the company’s strategic focus across innovation, growth, and international expansion.** Fung outlined how Airtasker differentiates itself in the local services marketplace by operating as a community platform, where both customers and taskers set job scopes and pricing, rather than the company enforcing set rates. He emphasised Airtasker’s approach to worker empowerment, noting, *“The top people on our platform are running 150, 200 thousand dollars a year doing these kinds of jobs.”* Fung also acknowledged the challenges of the current consumer environment, pointing to Airtasker’s 14.8% revenue growth in the half as a result of lean operations and renewed brand investment. A key part of Airtasker’s strategy involves innovation across customer acquisition, user experience, and operational efficiency—highlighting its collaboration with OpenAI and use of AI tools like Copilot and Zendesk AI. Fung also discussed partnerships, including one with Visa Cash App Racing Bulls, as examples of how Airtasker showcases the diverse range of skilled work enabled by the platform. He concluded by outlining the investor case: a cash-generative, proven business model in Australia being used to fund international growth in the US and UK, offering upside potential with limited downside. #Airtasker #TimFung #ASX #GigEconomy #AIIntegration #MarketplacePlatform #SmallCapStocks #TechInnovation #FY25Strategy #ProactiveInvestors #OpenAI #GlobalExpansion #InvestorUpdates #StartupGrowth

Proactive - Interviews for investors

Nextech3D.ai unveils AI-powered customer service chatbot, ushering new era of customer engagement

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to introduce the company’s latest innovation: an AI-powered customer service chat agent designed to enhance customer interactions and drive sales. This cutting-edge virtual assistant, integrated directly into Nextech3D.ai’s website, features advanced voice technology from Eleven Labs, enabling natural, human-like conversations. The AI chatbot is engineered to streamline customer support with a range of capabilities, including appointment scheduling, a dynamic knowledge base tailored to Nextech’s services, and seamless transitions to live representatives when needed. By leveraging artificial intelligence, Nextech aims to provide a frictionless, efficient, and engaging experience for its customers. Gappelberg emphasized that the adoption of AI chat agents marks a pivotal step in Nextech3D.ai’s evolution into an AI-first technology company, positioning it to compete at the highest level. The chatbot is not just a tool for customer engagement but also a powerful lead generation asset, automating appointment bookings and capturing high-quality leads to optimize service efficiency. By integrating this AI assistant, Nextech ensures that customers receive accurate, brand-aligned responses to their inquiries while maintaining the option for human support when necessary. With this move, Nextech3D.ai reaffirms its commitment to innovation and sets a new standard for AI-driven customer interactions. #nextech3d.al #otcqx #nexcf #cse #ntar #EvanGappelberg #AmazonSellerCentral #3DModeling #AIPhotography #EcommerceInnovation #3DTechnology #LifestylePhotography #ProactiveInterviews #TechInnovation #AmazonPartners#proactiveinvestors #nextech3d.al

Proactive - Interviews for investors

Actinogen targets $20B Alzheimer’s market with Xanamem

Actinogen Medical Ltd Managing Director and CEO Dr Stephen Gourlay talked with Proactive at the AIM's Small and Midcap conference about the company’s lead asset, Xanamem, and its development in Alzheimer’s disease and depression. Dr Gourlay explained that Xanamem is an oral, once-a-day drug designed to modulate cortisol levels in the brain without interfering with the body’s essential stress response. “We’ve also shown some positive data, you know, phase two and depression as well, which is very exciting because that validates its mechanism,” he said. He outlined the commercial opportunity in both Alzheimer’s and depression. While depression is more prevalent, the Alzheimer's market offers larger potential revenue. He noted that current treatments either have side effects or provide only temporary cognitive improvement, whereas Xanamem could modify the disease course with a better safety profile. Dr Gourlay discussed Actinogen’s recent momentum, including positive results in a depression trial, a number of peer-reviewed publications, and the upcoming interim analysis from its Alzheimer’s trial in Australia and the US. He said, “The upside from a positive Alzheimer’s trial is completely massive… a multi-billion dollar asset.” The company is currently trading below the total investment into drug development, which Dr Gourlay described as a compelling investment case. #Actinogen #Xanamem #AlzheimersResearch #DepressionTreatment #BiotechStocks #ClinicalTrials #Neuroscience #PharmaInnovation #ASX #ProactiveInvestors

Followers	21
Posts	1789
Boards Moderated	0
Alias Born	02/15/2021

Volume:	3
Day Range:
Bid:	8.32
Ask:	11.28
Last Trade Time:	4:24:05 AM EDT
Total Trades:	3

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

PLCE Detailed Quote

Recent PLCE News

More PLCE News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent PLCE News

Go Ad-Free